Alexion Pharmaceuticals Inc (ALXN)

118.86
0.40 0.34
NASDAQ : Health Care
Prev Close 119.26
Open 117.67
Day Low/High 115.58 / 119.05
52 Wk Low/High 110.56 / 205.29
Volume 2.40M
Avg Volume 2.14M
Exchange NASDAQ
Shares Outstanding 224.61M
Market Cap 27.01B
EPS 0.70
P/E Ratio 68.33
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Alexion Submits Application In Japan For Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Submits Application In Japan For Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) to extend the indication for Soliris ® (eculizumab) as a potential...

Alexion Pharmaceuticals Cuts 7% of Workforce

Alexion Pharmaceuticals Cuts 7% of Workforce

Alexion Pharmaceuticals is restructuring its business.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

FDA Accepts SBLA Filing Of Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

FDA Accepts SBLA Filing Of Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.

Alexion To Present At Upcoming Investor Conferences

Alexion To Present At Upcoming Investor Conferences

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017...

Alexion Pharma's Bloated Blockbuster Deal Still Haunts

Alexion Pharma's Bloated Blockbuster Deal Still Haunts

Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.

Alexion's Billion Dollar Deal Is Largely Wasted

Alexion's Billion Dollar Deal Is Largely Wasted

Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.

Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017

Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2016.

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.

Alexion Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Results On Thursday, February 16, 2017

Alexion Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Results On Thursday, February 16, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2016 on Thursday, February 16, 2017 before the US...

Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now

Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now

This drug maker has risen more than 17% this year. But investors may want to say cautious, unless they are super-aggressive.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris® (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris® (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company has submitted marketing applications to the U.

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.

Alexion To Present At The 35th Annual J.P. Morgan Healthcare Conference

Alexion To Present At The 35th Annual J.P. Morgan Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 35th Annual J.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016

Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced today that it has filed with the Securities and Exchange Commission its Form 10-Q for the third quarter ended September 30, 2016.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.